Skip to main content
editorial
. 2010 Sep 27;2(9):325–336. doi: 10.4254/wjh.v2.i9.325

Table 2.

Estimated incidence of cytomegalovirus disease during the first 12 mo after liver transplantation

Use of anti-cytomegalovirus prophylaxis
Yes1 (%) No (%)
CMV D+/R- 12-30 44-65
CMV D+/R+ 2.70 18.20
CMV D-/R+ 3.90 7.90
CMV D-/R- 0.00 0.00
All patients 4.80 18-29

D: donor; R: recipient; CMV: cytomegalovirus.

1

Most cases occur as delayed-onset CMV disease. CMV disease occurs rarely during prophylaxis with oral valganciclovir. Data adapted from references [4,5,77].